Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 7.1% – Here’s What Happened

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) traded down 7.1% on Wednesday . The stock traded as low as $1.77 and last traded at $1.83. 51,247 shares changed hands during trading, an increase of 551% from the average session volume of 7,871 shares. The stock had previously closed at $1.97.

Cyclerion Therapeutics Stock Performance

The business’s fifty day moving average price is $2.72 and its 200 day moving average price is $2.79.

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.

Featured Stories

• Five stocks we like better than Cyclerion Therapeutics
• Financial Services Stocks Investing
• Top-Performing Non-Leveraged ETFs This Year
• Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
• Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
• What is the S&P 500 and How It is Distinct from Other Indexes
• Freshworks Stock Soars 50% – Is This the Perfect Entry Point?